Great find. Some comments from this article:
Thanks for the article. I'm in CYDY. You have two stem-cell companies in your list. I assume you compared them to other stem-cell companies (PSTI, CAPR, CYYNF). What were the negatives on these others compared to MESO and ATHX?
Author’s reply » Good question. I favor MESO because of their compassionate use results, their progress in clinical trials, and their long history. I like ATHX because of their proprietary production process that can create great quantities of stem cells with ease. As far as I know, this is not the case with Pluristem or CAPR. I'm not familiar enough with CYYNF to comment. Thanks for reading the article and adding some names to the hunt.
Analysis of the EAP, page-444
-
- There are more pages in this discussion • 627 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39558 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 21776 | 3 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |